These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 37653509)
1. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature. Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509 [TBL] [Abstract][Full Text] [Related]
2. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398 [TBL] [Abstract][Full Text] [Related]
3. Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management. Yang Z; Wang Y; Chen Y; Qian F; Zhang Y; Hu M; Zhang W; Han B Eur J Cardiothorac Surg; 2022 Jul; 62(2):. PubMed ID: 35147672 [TBL] [Abstract][Full Text] [Related]
4. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma. Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941 [TBL] [Abstract][Full Text] [Related]
5. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086 [TBL] [Abstract][Full Text] [Related]
6. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib. Lim CA; Banyi N; Tucker T; Ionescu DN; Melosky B Curr Oncol; 2022 Feb; 29(2):848-852. PubMed ID: 35200571 [TBL] [Abstract][Full Text] [Related]
7. In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma. Hermans BCM; Derks JL; Hillen LM; van der Baan I; van den Broek EC; von der Thüsen JH; van Suylen RJ; Atmodimedjo PN; den Toom TD; Coumans-Stallinga C; Timens W; Dinjens WNM; Dubbink HJ; Speel EM; Dingemans AC; Int J Cancer; 2022 Mar; 150(5):802-815. PubMed ID: 34674268 [TBL] [Abstract][Full Text] [Related]
8. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538 [TBL] [Abstract][Full Text] [Related]
9. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831 [TBL] [Abstract][Full Text] [Related]
10. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906 [TBL] [Abstract][Full Text] [Related]
11. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma. Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429 [TBL] [Abstract][Full Text] [Related]
12. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC; Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508 [No Abstract] [Full Text] [Related]
13. Pathological features, clinical presentations and prognostic factors of ovarian large cell neuroendocrine carcinoma: a case report and review of published literature. Yang X; Chen J; Dong R J Ovarian Res; 2019 Jul; 12(1):69. PubMed ID: 31345245 [TBL] [Abstract][Full Text] [Related]
14. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC; Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341 [TBL] [Abstract][Full Text] [Related]
15. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488 [TBL] [Abstract][Full Text] [Related]
16. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833 [TBL] [Abstract][Full Text] [Related]
17. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638 [TBL] [Abstract][Full Text] [Related]
18. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas. Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma. Makino T; Mikami T; Hata Y; Otsuka H; Koezuka S; Isobe K; Tochigi N; Shibuya K; Homma S; Iyoda A Ann Thorac Surg; 2016 Nov; 102(5):1694-1701. PubMed ID: 27368130 [TBL] [Abstract][Full Text] [Related]
20. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]